Terremoto Biosciences, a biotechnology company leveraging the power of lysine-based covalency to develop optimized medicines, announced it has raised $75 million in a Series A financing. The round was co-led by OrbiMed and Third Rock Ventures.

Terremoto Biosciences is a covalent drug discovery and development engine creating highly targeted, small molecule medicines with unmatched selectivity, potency and efficacy. The company leverages the power of lysine-based covalency across the disease spectrum to develop both best-in-class therapies against known drug targets and first-in-class medicines against the previously undruggable. Many of Terremoto's founders helped establish this emergent area of science, with the intent to broaden the number of tractable targets and deliver medicines with superior therapeutic benefit.